Toll Free: 1-888-928-9744

B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2015

Dec 23, 2015 | 997 Pages | Global Markets Direct | Pharmaceuticals & Healthcare

B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2015', provides an overview of the B-Cell Non-Hodgkin Lymphoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of B-Cell Non-Hodgkin Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for B-Cell Non-Hodgkin Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the B-Cell Non-Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the B-Cell Non-Hodgkin Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for B-Cell Non-Hodgkin Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding B-Cell Non-Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 Introduction 8 B-Cell Non-Hodgkin Lymphoma Overview 9 Therapeutics Development 10 B-Cell Non-Hodgkin Lymphoma - Therapeutics under Development by Companies 12 B-Cell Non-Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes 22 B-Cell Non-Hodgkin Lymphoma - Pipeline Products Glance 23 B-Cell Non-Hodgkin Lymphoma - Products under Development by Companies 27 B-Cell Non-Hodgkin Lymphoma - Products under Investigation by Universities/Institutes 53 B-Cell Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development 55 B-Cell Non-Hodgkin Lymphoma - Therapeutics Assessment 166 Drug Profiles 192 B-Cell Non-Hodgkin Lymphoma - Recent Pipeline Updates 631 B-Cell Non-Hodgkin Lymphoma - Dormant Projects 945 B-Cell Non-Hodgkin Lymphoma - Discontinued Products 956 B-Cell Non-Hodgkin Lymphoma - Product Development Milestones 961 Appendix 972
List of Tables
Number of Products under Development for B-Cell Non-Hodgkin Lymphoma, H2 2015 34 Number of Products under Development for B-Cell Non-Hodgkin Lymphoma - Comparative Analysis, H2 2015 35 Number of Products under Development by Companies, H2 2015 37 Number of Products under Development by Companies, H2 2015 (Contd..1) 38 Number of Products under Development by Companies, H2 2015 (Contd..2) 39 Number of Products under Development by Companies, H2 2015 (Contd..3) 40 Number of Products under Development by Companies, H2 2015 (Contd..4) 41 Number of Products under Development by Companies, H2 2015 (Contd..5) 42 Number of Products under Development by Companies, H2 2015 (Contd..6) 43 Number of Products under Development by Companies, H2 2015 (Contd..7) 44 Number of Products under Development by Companies, H2 2015 (Contd..8) 45 Number of Products under Investigation by Universities/Institutes, H2 2015 46 Comparative Analysis by Late Stage Development, H2 2015 47 Comparative Analysis by Clinical Stage Development, H2 2015 48 Comparative Analysis by Early Stage Development, H2 2015 49 Comparative Analysis by Unknown Stage Development, H2 2015 50 Products under Development by Companies, H2 2015 51 Products under Development by Companies, H2 2015 (Contd..1) 52 Products under Development by Companies, H2 2015 (Contd..2) 53 Products under Development by Companies, H2 2015 (Contd..3) 54 Products under Development by Companies, H2 2015 (Contd..4) 55 Products under Development by Companies, H2 2015 (Contd..5) 56 Products under Development by Companies, H2 2015 (Contd..6) 57 Products under Development by Companies, H2 2015 (Contd..7) 58 Products under Development by Companies, H2 2015 (Contd..8) 59 Products under Development by Companies, H2 2015 (Contd..9) 60 Products under Development by Companies, H2 2015 (Contd..10) 61 Products under Development by Companies, H2 2015 (Contd..11) 62 Products under Development by Companies, H2 2015 (Contd..12) 63 Products under Development by Companies, H2 2015 (Contd..13) 64 Products under Development by Companies, H2 2015 (Contd..14) 65 Products under Development by Companies, H2 2015 (Contd..15) 66 Products under Development by Companies, H2 2015 (Contd..16) 67 Products under Development by Companies, H2 2015 (Contd..17) 68 Products under Development by Companies, H2 2015 (Contd..18) 69 Products under Development by Companies, H2 2015 (Contd..19) 70 Products under Development by Companies, H2 2015 (Contd..20) 71 Products under Development by Companies, H2 2015 (Contd..21) 72 Products under Development by Companies, H2 2015 (Contd..22) 73 Products under Development by Companies, H2 2015 (Contd..23) 74 Products under Development by Companies, H2 2015 (Contd..24) 75 Products under Development by Companies, H2 2015 (Contd..25) 76 Products under Investigation by Universities/Institutes, H2 2015 77 Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 78 B-Cell Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H2 2015 79 B-Cell Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc., H2 2015 80 B-Cell Non-Hodgkin Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015 81 B-Cell Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H2 2015 82 B-Cell Non-Hodgkin Lymphoma - Pipeline by Advancell, H2 2015 83 B-Cell Non-Hodgkin Lymphoma - Pipeline by Affimed Therapeutics AG, H2 2015 84 B-Cell Non-Hodgkin Lymphoma - Pipeline by Altor BioScience Corporation, H2 2015 85 B-Cell Non-Hodgkin Lymphoma - Pipeline by Amgen Inc., H2 2015 86 B-Cell Non-Hodgkin Lymphoma - Pipeline by AmpliMed Corporation (Inactive), H2 2015 87 B-Cell Non-Hodgkin Lymphoma - Pipeline by Aprogen, Inc., H2 2015 88 B-Cell Non-Hodgkin Lymphoma - Pipeline by arGEN-X BV, H2 2015 89 B-Cell Non-Hodgkin Lymphoma - Pipeline by Arrien Pharmaceuticals, LLC, H2 2015 90 B-Cell Non-Hodgkin Lymphoma - Pipeline by Arvinas, Inc., H2 2015 91 B-Cell Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc., H2 2015 92 B-Cell Non-Hodgkin Lymphoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2015 93 B-Cell Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, H2 2015 94 B-Cell Non-Hodgkin Lymphoma - Pipeline by Aurigene Discovery Technologies Limited, H2 2015 95 B-Cell Non-Hodgkin Lymphoma - Pipeline by Bayer AG, H2 2015 96 B-Cell Non-Hodgkin Lymphoma - Pipeline by BeiGene(Beijing) Co.,Ltd, H2 2015 97 B-Cell Non-Hodgkin Lymphoma - Pipeline by BIND Therapeutics, Inc., H2 2015 98 B-Cell Non-Hodgkin Lymphoma - Pipeline by Bio-Path Holdings, Inc., H2 2015 99 B-Cell Non-Hodgkin Lymphoma - Pipeline by Biocon Limited, H2 2015 100 B-Cell Non-Hodgkin Lymphoma - Pipeline by Biogenomics Limited, H2 2015 101 B-Cell Non-Hodgkin Lymphoma - Pipeline by Biothera, Inc., H2 2015 102 B-Cell Non-Hodgkin Lymphoma - Pipeline by Bluebird bio, Inc., H2 2015 103 B-Cell Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2015 104 B-Cell Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2015 105 B-Cell Non-Hodgkin Lymphoma - Pipeline by Calithera Biosciences, Inc., H2 2015 106 B-Cell Non-Hodgkin Lymphoma - Pipeline by Celgene Corporation, H2 2015 107 B-Cell Non-Hodgkin Lymphoma - Pipeline by Cell>Point, L.L.C., H2 2015 108 B-Cell Non-Hodgkin Lymphoma - Pipeline by Celltrion, Inc., H2 2015 109 B-Cell Non-Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H2 2015 110 B-Cell Non-Hodgkin Lymphoma - Pipeline by Coherus BioSciences, Inc., H2 2015 111 B-Cell Non-Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H2 2015 112 B-Cell Non-Hodgkin Lymphoma - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2015 113 B-Cell Non-Hodgkin Lymphoma - Pipeline by CTI BioPharma Corp., H2 2015 114 B-Cell Non-Hodgkin Lymphoma - Pipeline by Curis, Inc., H2 2015 115 B-Cell Non-Hodgkin Lymphoma - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015 116 B-Cell Non-Hodgkin Lymphoma - Pipeline by Dynavax Technologies Corporation, H2 2015 117 B-Cell Non-Hodgkin Lymphoma - Pipeline by Eisai Co., Ltd., H2 2015 118 B-Cell Non-Hodgkin Lymphoma - Pipeline by Eli Lilly and Company, H2 2015 119 B-Cell Non-Hodgkin Lymphoma - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015 120 B-Cell Non-Hodgkin Lymphoma - Pipeline by EpiZyme, Inc., H2 2015 121 B-Cell Non-Hodgkin Lymphoma - Pipeline by Erytech Pharma SA, H2 2015 122 B-Cell Non-Hodgkin Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 123 B-Cell Non-Hodgkin Lymphoma - Pipeline by Genentech, Inc., H2 2015 124 B-Cell Non-Hodgkin Lymphoma - Pipeline by Genmab A/S, H2 2015 125 B-Cell Non-Hodgkin Lymphoma - Pipeline by Genor BioPharma Co., Ltd., H2 2015 126 B-Cell Non-Hodgkin Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2015 127 B-Cell Non-Hodgkin Lymphoma - Pipeline by GlaxoSmithKline Plc, H2 2015 128 B-Cell Non-Hodgkin Lymphoma - Pipeline by Hutchison MediPharma Limited, H2 2015 129 B-Cell Non-Hodgkin Lymphoma - Pipeline by Idera Pharmaceuticals, Inc., H2 2015 130 B-Cell Non-Hodgkin Lymphoma - Pipeline by IGF Oncology, LLC., H2 2015 131 B-Cell Non-Hodgkin Lymphoma - Pipeline by ImmunoGen, Inc., H2 2015 132 B-Cell Non-Hodgkin Lymphoma - Pipeline by Immunomedics, Inc., H2 2015 133 B-Cell Non-Hodgkin Lymphoma - Pipeline by Immunovaccine, Inc., H2 2015 134 B-Cell Non-Hodgkin Lymphoma - Pipeline by Incyte Corporation, H2 2015 135 B-Cell Non-Hodgkin Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2015 136 B-Cell Non-Hodgkin Lymphoma - Pipeline by Inflection Biosciences Limited, H2 2015 137 B-Cell Non-Hodgkin Lymphoma - Pipeline by Johnson & Johnson, H2 2015 138 B-Cell Non-Hodgkin Lymphoma - Pipeline by Juno Therapeutics Inc., H2 2015 139 B-Cell Non-Hodgkin Lymphoma - Pipeline by Karus Therapeutics Limited, H2 2015 140 B-Cell Non-Hodgkin Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 141 B-Cell Non-Hodgkin Lymphoma - Pipeline by Kite Pharma, Inc., H2 2015 142 B-Cell Non-Hodgkin Lymphoma - Pipeline by Les Laboratoires Servier SAS, H2 2015 143 B-Cell Non-Hodgkin Lymphoma - Pipeline by LFB S.A., H2 2015 144 B-Cell Non-Hodgkin Lymphoma - Pipeline by Mabion SA, H2 2015 145 B-Cell Non-Hodgkin Lymphoma - Pipeline by mAbxience S.A., H2 2015 146 B-Cell Non-Hodgkin Lymphoma - Pipeline by MedImmune, LLC, H2 2015 147 B-Cell Non-Hodgkin Lymphoma - Pipeline by Medivation, Inc., H2 2015 148 B-Cell Non-Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H2 2015 149 B-Cell Non-Hodgkin Lymphoma - Pipeline by Merck KGaA, H2 2015 150 B-Cell Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 151 B-Cell Non-Hodgkin Lymphoma - Pipeline by Mirati Therapeutics Inc., H2 2015 152 B-Cell Non-Hodgkin Lymphoma - Pipeline by Mirna Therapeutics, Inc., H2 2015 153 B-Cell Non-Hodgkin Lymphoma - Pipeline by Molecular Templates Inc., H2 2015 154 B-Cell Non-Hodgkin Lymphoma - Pipeline by Molplex Ltd., H2 2015 155 B-Cell Non-Hodgkin Lymphoma - Pipeline by MorphoSys AG, H2 2015 156 B-Cell Non-Hodgkin Lymphoma - Pipeline by Neumedicines Inc., H2 2015 157 B-Cell Non-Hodgkin Lymphoma - Pipeline by Nimbus Therapeutics, LLC, H2 2015 158 B-Cell Non-Hodgkin Lymphoma - Pipeline by Nordic Nanovector ASA, H2 2015 159 B-Cell Non-Hodgkin Lymphoma - Pipeline by Novartis AG, H2 2015 160 B-Cell Non-Hodgkin Lymphoma - Pipeline by NovImmune SA, H2 2015 161 B-Cell Non-Hodgkin Lymphoma - Pipeline by Onconova Therapeutics, Inc., H2 2015 162 B-Cell Non-Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 163 B-Cell Non-Hodgkin Lymphoma - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015 164 B-Cell Non-Hodgkin Lymphoma - Pipeline by Pfizer Inc., H2 2015 165 B-Cell Non-Hodgkin Lymphoma - Pipeline by Pharmacyclics, Inc., H2 2015 166 B-Cell Non-Hodgkin Lymphoma - Pipeline by Philogen S.p.A., H2 2015 167 B-Cell Non-Hodgkin Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H2 2015 168 B-Cell Non-Hodgkin Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H2 2015 169 B-Cell Non-Hodgkin Lymphoma - Pipeline by RedHill Biopharma Ltd., H2 2015 170 B-Cell Non-Hodgkin Lymphoma - Pipeline by Redx Pharma Plc, H2 2015 171 B-Cell Non-Hodgkin Lymphoma - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015 172 B-Cell Non-Hodgkin Lymphoma - Pipeline by Respiratorius AB, H2 2015 173 B-Cell Non-Hodgkin Lymphoma - Pipeline by Rhizen Pharmaceuticals S.A., H2 2015 174 B-Cell Non-Hodgkin Lymphoma - Pipeline by Sandoz International GmbH, H2 2015 175 B-Cell Non-Hodgkin Lymphoma - Pipeline by Sanofi, H2 2015 176 B-Cell Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2015 177 B-Cell Non-Hodgkin Lymphoma - Pipeline by Selvita SA, H2 2015 178 B-Cell Non-Hodgkin Lymphoma - Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2015 179 B-Cell Non-Hodgkin Lymphoma - Pipeline by Sorrento Therapeutics, Inc., H2 2015 180 B-Cell Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015 181 B-Cell Non-Hodgkin Lymphoma - Pipeline by Stemline Therapeutics, Inc., H2 2015 182 B-Cell Non-Hodgkin Lymphoma - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2015 183 B-Cell Non-Hodgkin Lymphoma - Pipeline by Takara Bio Inc., H2 2015 184 B-Cell Non-Hodgkin Lymphoma - Pipeline by TG Therapeutics, Inc., H2 2015 185 B-Cell Non-Hodgkin Lymphoma - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2015 186 B-Cell Non-Hodgkin Lymphoma - Pipeline by Theravectys SA, H2 2015 187 B-Cell Non-Hodgkin Lymphoma - Pipeline by Unum Therapeutics, Inc., H2 2015 188 B-Cell Non-Hodgkin Lymphoma - Pipeline by Vivolux AB, H2 2015 189 Assessment by Monotherapy Products, H2 2015 190 Assessment by Combination Products, H2 2015 191 Number of Products by Stage and Target, H2 2015 193 Number of Products by Stage and Mechanism of Action, H2 2015 204 Number of Products by Stage and Route of Administration, H2 2015 213 Number of Products by Stage and Molecule Type, H2 2015 215 B-Cell Non-Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H2 2015 655 B-Cell Non-Hodgkin Lymphoma - Dormant Projects, H2 2015 969 B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..1), H2 2015 970 B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..2), H2 2015 971 B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..3), H2 2015 972 B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..4), H2 2015 973 B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..5), H2 2015 974 B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..6), H2 2015 975 B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..7), H2 2015 976 B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..8), H2 2015 977 B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..9), H2 2015 978 B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..10), H2 2015 979 B-Cell Non-Hodgkin Lymphoma - Discontinued Products, H2 2015 980 B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..1), H2 2015 981 B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..2), H2 2015 982 B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..3), H2 2015 983 B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..4), H2 2015 984


List of Figures
Number of Products under Development for B-Cell Non-Hodgkin Lymphoma, H2 2015 34 Number of Products under Development for B-Cell Non-Hodgkin Lymphoma - Comparative Analysis, H2 2015 35 Number of Products under Development by Companies, H2 2015 36 Number of Products under Investigation by Universities/Institutes, H2 2015 46 Comparative Analysis by Late Stage Development, H2 2015 47 Comparative Analysis by Clinical Stage Development, H2 2015 48 Comparative Analysis by Early Stage Products, H2 2015 49 Assessment by Monotherapy Products, H2 2015 190 Assessment by Combination Products, H2 2015 191 Number of Products by Top 10 Targets, H2 2015 192 Number of Products by Stage and Top 10 Targets, H2 2015 192 Number of Products by Top 10 Mechanism of Actions, H2 2015 203 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 203 Number of Products by Routes of Administration, H2 2015 212 Number of Products by Stage and Routes of Administration, H2 2015 212 Number of Products by Top 10 Molecule Types, H2 2015 214 Number of Products by Stage and Top 10 Molecule Types, H2 2015 214

To request a sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global adhesives & sealants market size is expected to reach USD 43.19 billion by 2020, as per a new research report by Radiant Insights, Inc. Strong demand from packaging, construction and automotive industries is expected drive adhesives and sealan

Read More...October 6, 2015

Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expected

Read More...October 23, 2015

Global alpha olefins market size is likely to be valued at USD 10.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing polyethylene demand for use in plastic production is anticipated to drive market growth. Growing ap

Read More...October 26, 2015

Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanom

Read More...October 6, 2015

Global PP (Polypropylene) nonwoven fabric market size is anticipated to be valued at USD 30.6 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing usage of hygiene products such as incontinence products and baby diapers is

Read More...October 9, 2015
Choose License Type
Single User - US$ 2500.00
Multi User - US$ 5000.00
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify